NEWS
Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders
Tuesday, 10th June at 9:03 am
Patent-protected aminated tryptamine derivatives strengthen Enveric's leadership in next-generation mental health treatments
Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application covering compositions of matter and methods of use for a novel class of aminated tryptamine derivatives.
The patented compounds were designed through Enveric's proprietary discovery platform and represent a first-in-class approach to non-hallucinogenic psychedelic-inspired therapeutics. The compounds demonstrated low hallucinogenic liability in preclinical testing, including minimal Head Twitch Response (HTR) and reduced 5-HT2A receptor activation – two established indicators of hallucinogenic activity in rodents.
"The allowance of this application adds a new tier of patent-protected innovation to our pipeline of non-hallucinogenic neuroplastogens," said Joseph Tucker, Ph.D., CEO of Enveric. "Unlike traditional psychedelics that require intensive clinical monitoring due to their hallucinogenic effects, our molecules are designed for frequent, flexible, outpatient dosing, which we expect will be better aligned with patient lifestyles, clinics workflows, and payers established models."
Tuesday, 10th June at 9:03 am
Patent-protected aminated tryptamine derivatives strengthen Enveric's leadership in next-generation mental health treatments
Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application covering compositions of matter and methods of use for a novel class of aminated tryptamine derivatives.
The patented compounds were designed through Enveric's proprietary discovery platform and represent a first-in-class approach to non-hallucinogenic psychedelic-inspired therapeutics. The compounds demonstrated low hallucinogenic liability in preclinical testing, including minimal Head Twitch Response (HTR) and reduced 5-HT2A receptor activation – two established indicators of hallucinogenic activity in rodents.
"The allowance of this application adds a new tier of patent-protected innovation to our pipeline of non-hallucinogenic neuroplastogens," said Joseph Tucker, Ph.D., CEO of Enveric. "Unlike traditional psychedelics that require intensive clinical monitoring due to their hallucinogenic effects, our molecules are designed for frequent, flexible, outpatient dosing, which we expect will be better aligned with patient lifestyles, clinics workflows, and payers established models."
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Your actions are your signature—karma is the ink that never fades. Truth walks, lies limp.
14K
Followers
33
Following
201K
Visitors
Follow
Market Insights
Popular Gold Mining Stocks Popular Gold Mining Stocks
Amidst the uncertain outlook of the trade war and escalating concerns about an economic recession, gold prices have repeatedly reached new highs this year, at one point surpassing $3,500 per ounce. This marks an almost 30% increase since the beginning of the year. For investors in U.S. equities, investing in gold mining stocks represents a significant opportunity to ride this wave. Amidst the uncertain outlook of the trade war and escalating concerns about an economic recession, gold prices have repeatedly reached new highs this year, at one point surpassing $3,500 per ounce. This marks an almost 30% increase since the beginning of the year. For investors in U.S. equities, investing in gold mining stocks represents a significant opportunity to ride this wave.
Unlock Now
Discussing
Trump threatens tariffs on EU, how will markets react?
1. How do you think Trump's tariff threats will impact short-term trends in European and U.S. stocks? 2. Amid tariff negotiation uncertainti
Moo Options Explorer
Apr 7 17:28
Weekly roundup: Tariff turmoil and recession fears dominate
MOHD NOR B ABDULLAH : Tq info
Arrayfunction : I hope this plays out and someone gets a drug in this class to market. I always get nervous seeing 5-HT2A as a target though. Agonism means psychosis as a possible side effect; antagonism means possible permanent neurological damage in limb control. Anti-psychotics are some very dangerous things companies play fast and loose to broaden indications as "auxiliary". Thanks for sharing!
Arrayfunction Arrayfunction : Though admittedly, it's the D2 dopamine activity that is more likely to cause the permanent tardive dyskinesia. (not super relevant, just don't want to spread false info?
103932675 : I bought this at 86...and since the stock split a few times...can anyone shed some light on this pls